PMID- 29028997
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20181202
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
VI  - 158
IP  - 12
DP  - 2017 Dec 1
TI  - Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of 
      Insulin Resistance in Male Mice and Humans.
PG  - 4152-4164
LID - 10.1210/en.2017-00339 [doi]
AB  - To identify circulating factors as candidates involved in type 2 diabetes 
      mellitus (T2DM), we conducted two different quantitative proteomic analyses: (1) 
      db/db mouse sera were compared with db/+ mouse sera obtained at 4, 8, 12, and 24 
      weeks of age, and (2) db/db mouse sera from animals treated with liraglutide were 
      compared with sera from animals without liraglutide treatment. Twenty proteins 
      were differentially expressed in db/db mouse sera in the first experiment and 
      eight proteins were differentially expressed in db/db mouse sera after 
      liraglutide treatment in the second experiment. Soluble epidermal growth factor 
      receptor (sEGFR) was identified as a common factor, and its protein level was 
      significantly affected in both experiments. An enzyme-linked immunosorbent assay 
      confirmed that the relatively low serum sEGFR levels in db/db mice were restored 
      by liraglutide treatment. The serum sEGFR levels were elevated in diabetic mice 
      with impaired insulin secretion and decreased in high-fat diet-fed mice and ob/ob 
      mice. The serum sEGFR levels increased after the administration of a dual 
      inhibitor of IGF-1/insulin receptor or streptozotocin. In humans with normal 
      glucose tolerance or T2DM, the serum sEGFR levels were correlated with the 
      fasting blood glucose, fasting serum insulin, homeostatic model assessment of 
      insulin resistance, HbA1c, total cholesterol, low-density lipoprotein 
      cholesterol, and triglycerides levels. These findings suggest that sEGFR might be 
      a biomarker for evaluating insulin resistance or a therapeutic target of 
      liraglutide.
CI  - Copyright (c) 2017 Endocrine Society.
FAU - Kyohara, Mayu
AU  - Kyohara M
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
FAU - Shirakawa, Jun
AU  - Shirakawa J
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
FAU - Okuyama, Tomoko
AU  - Okuyama T
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
FAU - Kimura, Ayuko
AU  - Kimura A
AD  - Advanced Medical Research Center, Yokohama City University, Japan.
FAU - Togashi, Yu
AU  - Togashi Y
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
FAU - Tajima, Kazuki
AU  - Tajima K
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
FAU - Hirano, Hisashi
AU  - Hirano H
AD  - Advanced Medical Research Center, Yokohama City University, Japan.
FAU - Terauchi, Yasuo
AU  - Terauchi Y
AD  - Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama 
      City University, Japan.
LA  - eng
SI  - UMIN CTR/UMIN000020474
PT  - Journal Article
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (Proteome)
RN  - 839I73S42A (Liraglutide)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Biomarkers/*blood
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/blood/drug therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - ErbB Receptors/antagonists & inhibitors/*blood
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - Insulin/blood
MH  - *Insulin Resistance
MH  - Lipids/blood
MH  - Liraglutide/pharmacology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Proteome/*metabolism
MH  - Proteomics/*methods
EDAT- 2017/10/14 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/10/14 06:00
PHST- 2017/04/07 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/10/14 06:00 [entrez]
AID - 4344850 [pii]
AID - 10.1210/en.2017-00339 [doi]
PST - ppublish
SO  - Endocrinology. 2017 Dec 1;158(12):4152-4164. doi: 10.1210/en.2017-00339.